NeoPharm Dividends and Buybacks
Dividend criteria checks 2/6
NeoPharm is a dividend paying company with a current yield of 3.25% that is well covered by earnings. Next payment date is on 9th April, 2025 with an ex-dividend date of 27th December, 2024.
Key information
3.3%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | 3.3% |
| Dividend Growth | 9.7% |
| Next dividend pay date | 09 Apr 25 |
| Ex dividend date | 27 Dec 24 |
| Dividend per share | ₩375.000 |
| Payout ratio | 26% |
Recent dividend and buyback updates
Recent updates
We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings
Nov 20
The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence
Nov 13NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, A092730 has been paying a dividend for less than 10 years.
Growing Dividend: A092730's dividend payments have increased, but the company has only paid a dividend for 5 years.
Dividend Yield vs Market
| NeoPharm Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (A092730) | 3.3% |
| Market Bottom 25% (KR) | 1.2% |
| Market Top 25% (KR) | 3.9% |
| Industry Average (Personal Products) | 1.1% |
| Analyst forecast (A092730) (up to 3 years) | 3.3% |
Notable Dividend: A092730's dividend (3.25%) is higher than the bottom 25% of dividend payers in the KR market (1.19%).
High Dividend: A092730's dividend (3.25%) is low compared to the top 25% of dividend payers in the KR market (3.94%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (26.3%), A092730's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: A092730 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 03:33 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NeoPharm CO., LTD. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiseon An | DAOL Investment & Securities Co., Ltd. |
| Sunhwa Lee | Eugene Investment & Securities Co Ltd. |
| Byung-Ki Kim | Hanwha Investment & Securities Co., Ltd. |